Drugs / ACE1702
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04319757 | Jun 2020 → Jul 2024 | HER2 positive breast carcinoma, metastatic malignant neoplasm | Acepodia Biotech, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACE1702 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04319757 ↗ |
| Modality | Cell therapy | “ACE1702 cellular therapy” NCT04319757 ↗ |
| Route | Intravenous | “given intravenously” NCT04319757 ↗ |